Anti-Vaccine Rhetoric's Impact on Vaccine Makers and Public Health

Impact of Anti-Vaccine Rhetoric

• ⚠️ The general anti-vaccine rhetoric is detrimental to public health, extending beyond COVID-19 vaccines to affect routine immunizations like HPV and MMR.
• 🎯 While COVID-19 vaccines are a small portion of sales for companies like Pfizer, the rhetoric creates a cascading effect on other essential vaccines.
• 🏥 Rhetoric originating from specific regions, such as Florida, is also noted as unhelpful.

Insurer and Pharmacist Roles

• 💰 The actions of insurers will be key in determining how vaccine recommendations are viewed, specifically if they continue to pay for vaccines despite ASIP recommendations.
• 🧑‍⚕️ The availability of vaccines through pharmacists without a prescription is highlighted as an important factor for accessibility.
• 🚫 It is unlikely that common vaccines like MMR and HPV will be removed or uninsured, as this could cause significant backlash.

COVID-19 Vaccine as a Flashpoint

• 📈 The COVID-19 vaccine is seen as a political push rather than a public health problem, with debates focusing on data rather than the diseases themselves.
• 📊 While the diseases are public health issues, the use of the vaccines is framed as a point of contention.

Investor Focus and Company Diversification

• 🏢 For companies like Pfizer, vaccines are a shrinking part of the business, with a strategic shift towards areas like oncology.
• 🤝 Partnerships, such as the one with Bristol Myers for lung cancer treatments, are crucial for future revenue streams.
• 📉 While headlines about vaccine rhetoric can make investors jittery, the focus is shifting away from vaccines to other business segments.

Key Data from Diabetes Meeting

• 🔬 The upcoming diabetes meeting in Europe will focus on Orforglipron data, aiming to understand its underperformance and clinician feedback.
• ❓ Key questions include the acceptability of efficacy rates (11-12% vs. 16%) and nausea/vomiting rates.
• 🍽️ The impact of food effect on oral semaglutide and its potential headwinds for Novo Nordisk in real-world use will also be examined.